Table 2.
Cell lines IC50[μM] | |||||||||
---|---|---|---|---|---|---|---|---|---|
Cpd |
R1 |
R2 |
R3 |
R4 |
M14 |
MCF-7 |
PC3 |
A498 |
A375 |
I |
H |
H |
H |
|
>100 |
>100 |
>100 |
>100 |
>100 |
II |
n-hexyl |
H |
H |
|
23 ± 0.12 |
28.13 ± 0.07 |
41 ± 0.20 |
34.91 ± 3.82 |
>100 |
III |
H |
H |
H |
|
>100 |
>100 |
>100 |
>100 |
>100 |
IV |
n-hexyl |
H |
H |
|
45.6 ± 0.20 |
37.3 ± 0.34 |
38 ± 0.12 |
28.8 ± 0.04 |
30.7 ± 0.12 |
V |
n-hexyl |
H |
H |
H |
7.0 ± 0.10 |
18.7 ± 0.06 |
24.3 ± 0.20 |
19.8 ± 0.02 |
12.9 ± 0.06 |
VI |
H |
n-hexyl |
H |
H |
- |
>100 |
>100 |
>100 |
>100 |
VII |
H |
n-hexyl |
CH3 |
H |
- |
>100 |
>100 |
>100 |
>100 |
VIII |
H |
H |
CH3 |
n-hexyl |
- |
>100 |
>100 |
>100 |
>100 |
IX |
-CH3 |
n-butyl |
CH3 |
H |
24.5 ± 0.15 |
12 ± 0.03 |
17.9 ± 0.20 |
51 ± 0.02 |
17.6 ± 0.05 |
X |
H |
n-butyl |
CH3 |
H |
35 ± 0.64 |
>100 |
>100 |
>100 |
>100 |
XI |
H |
n-butyl |
H |
H |
>100 |
>100 |
>100 |
>100 |
>100 |
XII |
-CH3 |
n-hexyl |
CH3 |
H |
10.7 ± 0.15 |
16.2 ± 0.03 |
18.8 ± 0.03 |
>100 |
21.0 ± 0.04 |
XIII |
H |
n-hexyl |
CH3 |
H |
14.1 ± 0.15 |
13.9 ± 0.04 |
20.1 ± 0.20 |
>100 |
18.1 ± 0.04 |
XIV |
H |
n-hexyl |
H |
H |
>100 |
>100 |
>100 |
>100 |
>100 |
H331 | 15.0 ± 0.09 | 24.5 ± 0.15 | 32.0 ± 0.15 | 34.6 ± 0.23 | 21.8 ± 0.03 |
Cell viability was assessed through MTT assay. Data represent the mean ± SD values of three independent determinations performed in triplicate. A375, M14, human melanoma cells; MCF-7, human breast cancer cells; PC3, Human prostate cancer cell line, A498, Human renal cancer cell line.